IASLC World Conference on Lung Cancer (WCLC)

Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer.

Adjuvant atezolizumab led to disease-free survival benefit in patients with early-stage non–small cell lung cancer, including most patient subgroups, in the phase 3 IMpower010 trial.

Patients with non–small cell lung cancer harboring ALK mutations who were not suitable for crizotinib therapy, either due to resistance or intolerance, showed benefit with sequential crizotinib and alectinib.

Patients with non-small cell lung cancer with brain metastases experienced a favorable safety profile along with efficacy results when treated with atezolizumab plus chemotherapy.

Strategies from the COVID-19 pandemic such as flexible, patient-focused approaches and telehealth may work to increase enrollment on clinical lung cancer trials by increasing accessibility.

CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about KRAS as a therapy biomarker in lung cancer.

The phase 3 POSEIDON trial indicated that patients with metastatic non–small cell lung cancer who were treated with first-line durvalumab and chemotherapy with or without tremelimumab experienced a statistically significant survival benefit.

Patients with EGFR-mutated non–small cell lung cancer who were treated with ado-trastuzumab emtansine and osimertinib experienced minimal anti-tumor outcomes.

Previously platinum-treated patients with EGFR exon 20 insertion mutation–positive non–small cell lung cancer saw clinical activity with mobocertinib regardless of prior PD-1/PD-L1 inhibitor history.

In the early days of the COVID-19 pandemic, patients with malignant pleural mesothelioma were more likely to be hospitalized or die from COVID-19 versus the overall population.

Durable efficacy and a manageable safety profile were observed with selpercatinib for Chinese patients with advanced, RET fusion–positive non–small cell lung cancer.

For patients with KRAS G12C–mutated non–small cell lung cancer and stable brain metastases who were previously treated with either radiation or surgery, robust anticancer activity was observed with intracranial complete responses and continued intracranial stabilization with sotorasib.

Patients with EGFR-positive non–small cell lung cancer whose disease is not suitable for standard EGFR TKI monotherapy had promising responses and experienced few dose-limiting toxicities with pelcitoclax plus osimertinib.

Patients with stage IIIB and stage IV advanced squamous non–small cell lung cancer experienced a clinically significant improvement in progression-free survival with tislelizumab plus chemotherapy in the first-line setting compared with standard of care chemotherapy.

Data from the ARROW study demonstrated safety and efficacy of pralsetinib in a cohort of Chinese patients with RET fusion–positive non–small cell lung cancer.

In a phase 1/2 trial, the selective targeting of EGFR exon 20 insertion mutations with mobocertinib in patients with previously treated non–small cell lung cancer resulted in superior patient-reported outcomes.

The KEYNOTE-010 study evaluated the use of either pembrolizumab or docetaxel in patients with previously treated, PD-L1–positive advanced non–small cell lung cancer.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed how she hopes the results of the KEYNOTE-799 study will impact testing going forward.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed the adverse events associated with the use of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey spoke about the possible implications of the KEYNOTE-799 study findings.

The chief of Gastrointestinal Radiation Oncology at the Rutgers Cancer Institute of New Jersey discussed updated results from the study of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

The trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI–refractory composite AXL (cAXL)–positive non–small cell lung cancer.

The KEYNOTE-799 study is evaluating pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non–small cell lung cancer.

The ongoing phase 2 BGBC008 trial demonstrated that combination treatment with bemcentinib and pembrolizumab was well tolerated and clinically active in patients with checkpoint inhibitor (CPI)–naïve and CPI-refractory composite AXL-positive non–small cell lung cancer.

Data on patients with EGFR-mutant non–small cell lung cancer and brain metastases showed the ability of [11C]osimertinib to reduce metastatic volume and achieve consistent brain penetration.

Patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, appeared to be effective at the recommended expansion dose of 5.6 mg/kg in patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer based on clinically meaningful antitumor activity and a manageable safety profile.

Patients with extensive-stage small cell lung cancer show greater response when atezolizumab is added to carboplatin and etoposide versus placebo in the IMpower133 trial.

According to trial investigators, the results of the ongoing BFBC008 study point support the continued development of AXL inhibition with bemcentinib in order to extend the efficacy of immunotherapy in biomarker-selected refractory non–small cell lung cancer.

The MET inhibitor tepotinib demonstrated durable clinical activity in non‒small cell lung cancer tumors harboring MET exon 14 skipping mutations.

“Preliminary TRIDENT-1 data are very encouraging and support repotrectinib as a potential best-in-class treatment in ROS1-positive advanced NSCLC,” according to Byoung Chul Cho, MD, PhD.